Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4752095 | 0.84 | ALDH1A1 (0.48) | HPGDKDM4ELMNAALDH1A1GAA | |
| SCHEMBL4752576 | 0.81 | KMT2A (0.43) | MEN1KMT2AKDM4ETSHRLMNA | |
| SCHEMBL4752657 | 0.80 | SMN1; SMN2 (0.50) | MEN1KMT2AHPGDTSHRLMNA | |
| SCHEMBL4751893 | 0.79 | MGLL (0.42) | MEN1KMT2AHPGDKDM4ELMNA | |
| SCHEMBL4288263 | 0.79 | NPSR1 (0.43) | MEN1KMT2AHPGDKDM4ETSHR | |
| SCHEMBL4753584 | 0.78 | ALDH1A1 (0.46) | KMT2AHPGDLMNAALDH1A1MAPT | |
| SCHEMBL4298262 | 0.78 | ALDH1A1 (0.45) | MEN1KMT2ALMNAALDH1A1GAA | |
| SCHEMBL4750109 | 0.77 | ALDH1A1 (0.40) | MEN1KMT2AHPGDKDM4ELMNA | |
| SCHEMBL4752523 | 0.77 | ABHD6 (0.43) | MEN1KMT2AKDM4EALDH1A1GAA | |
| SCHEMBL4753413 | 0.76 | TDP1 (0.51) | MEN1KMT2AHPGDTSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MEN1 1254/4885KMT2A 1049/4885HPGD 106/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | MEN1 1254/4885KMT2A 1049/4885HPGD 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.